Taking a broader look at the analyst consensus, according to 6 analysts Novavax Inc (NASDAQ:NVAX)'s price will reach at $3.25 during 52 weeks.
Novavax Inc (NASDAQ:NVAX) shares traded on -1.48% below secure line and closed at $2. Citigroup raised shares of Novavax from a "neutral" rating to a "buy" rating and set a $2.00 price target for the company in a research note on Tuesday, October 31st.
Novavax, Inc. (NVAX) has the market capitalization of $636.6 Million. Following the completion of the acquisition, the insider now owns 228,279 shares of the company's stock, valued at $257,955.27. It would take about 4.72 days to cover all short positions. The Firm has ATR of 0.15 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price if it was outside of latest range. Stock's distance from 52 week High is -13.79% and the distance from 52 week Low is 173.97%.
A total of 8.56 Billion shares exchanged at hands and its average trading volume is standing at 9.46 Million shares. The relative volume of the stock is 0.9. The other 2, though not evenly; between analysts who think you should buy Novavax, Inc. versus those who think you should sell it. The stock jumped 106.48 percent over the past six months.
Stock's free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is -7.5. The Return on Investment and Return on Equity (ROE) values are 0 percent and 452.8 percent, respectively. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28.
ILLEGAL ACTIVITY NOTICE: "Novavax (NASDAQ:NVAX) Given News Impact Score of 0.10" was originally reported by StockNewsTimes and is the property of of StockNewsTimes.
Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also helps in determining where it may be possibly heading. Novavax Inc (NASDAQ:NVAX)'s price sits 29.17% above from its SMA 50 of $1.65 and 67.7% far from the SMA 200 which is at $1.28.
Analysts are expecting average earnings estimates of $-0.15 for the current quarter based on the opinion of 8 analysts, relating to high earnings per share estimates of $-0.14 and low estimates of $-0.18, however Novavax Inc (NASDAQ:NVAX) reported $-0.21 earnings per share for the same quarter a year ago.
EPS Growth this year is -72.8 percent. However a year ago for the same quarter the company has reported $-0.21 EPS. Novavax, Inc. earnings have declined with an annualized rate of -43.4% over the last 5 years. The company's revenue for the quarter was up 158.5% on a year-over-year basis. Three analysts have provided estimates for Novavax's earnings, with the highest sales estimate coming in at $10.30 million and the lowest estimate coming in at $6.00 million. Its book value per share for the most recent quarter is $-0.25 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.54, however its price to cash per share ratio for the same period is 3.69. This shows a surprise factor of 0.087%.
The company is estimated to report earnings on Feb 26 AMC. Zacks' sales calculations are a mean average based on a survey of research analysts that follow Novavax.
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.
Atlanta group studies Super Bowl, set to go 'on the clock'
It's not known what songs he'll perform during the 13-minute performance - that's the standard length for Super Bowl shows. Trump already eschewed one Super Bowl tradition by declining to grant an interview to NBC, which broadcasts the game.
Stock markets plunge following record U.S. slump
On the currency markets, the pound was flat at 1.395 against the United States dollar and was 0.1% lower versus the euro at 1.127. The selloff in stocks that began last week has been built on concerns over higher interest rates and lofty valuations.
Another Government Shutdown Looming as Deadline Approaches
But it is narrower in scope than a plan Trump put forward last month, which was resisted by hardline Republicans and Democrats. He noted extension of the Deferred Action for Childhood Arrivals program was "beyond what anyone could have imagined".